Nicholas Giovannone, PhD, a senior principal scientist at Regeneron, also discussed the problem of preexisting immunity caused by natural exposure to AAVs.
Nicholas Giovannone, PhD
Advertisement
Senior principal scientist at Regeneron
Articles by Nicholas Giovannone, PhD
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron, discussed an advanced approach to enabling gene therapy redosing.
The senior principal scientist at Regeneron also discussed the problem of preexisting immunity caused by natural exposure to AAVs.
The senior principal scientist at Regeneron discussed an advanced approach to enabling gene therapy redosing.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
FDA Picks Abeona’s XLRS Gene Therapy ABO-503 for RDEA Pilot Program
2
Krystal Biotech’s Neurotrophic Keratitis Gene Therapy Viral Vector Secures FDA Platform Technology Designation
3
BLA for Rocket’s LAD-I Gene Therapy Under Review by FDA Again
4
